Join our ELEVATE Clinical Study today. Sign-up now

Whitepaper

img white paper 1 thumbnail

New lupus therapies target the IFN-1 pathway

New data shows IFN-1 high patients have a better response to certain therapies

 

IFN-1 Test for Lupus

WHITE PAPER

Two new lupus therapies target the influential IFN-1 pathway

  • The key role of IFN-1 in the progression of lupus
  • How a patient’s IFN-1 status may affect response to standard therapy
  • Specific mechanisms of action of 2 new therapies that interrupt the IFN-1 pathway
  • Studies and data featuring patient response to belimumab and anifrolumab
img white paper 1 thumbnail

 

learn_IFN-1.png

Want to learn more about IFN-1 and its role in SLE progression?

 

View our additional resources:

IFN-1 White paper

IFN-1 Informational Brochure

 

 

 

Two new therapies, targeting molecules within the influential Interferon Type 1 (IFN-1) signaling cascade, have been shown to benefit some patients that do not respond well to standard therapies.

List of illness Copy

After years of limited therapeutic options for lupus, the development of personalized treatments offers hope to patients struggling to control their disease.

 

 

Better health management begins
at home

Subscribe to receive the latest information on new developments and products at DxTerity.